Emmaus Life Sciences, Inc. 10-Q

Item 5. Other Information None. 29 Item 6. Exhibits (a) Exhibits Incorporated by Reference Exhibit Number Exhibit Description Form File No. Exhibit Filing Date Filed/ Furnished 10.1 Promissory Note dated January 20, 2021 issued by registrant to Soomi Niihara * 10.2 Promissory Note dated February 17, 2021 issued by registrant to Shigeru Matsuda * 10.3 Securities Purchase Agreement dated as of February 8, 2021 among Emmaus Life Sciences, Inc. and the "Purchasers" Thereunder 8-K 001-35527 10.1 February 16, 2021 10.4 Transfer Restriction and Voting Agreement dated February 8, 2021 between Emmaus Life Sciences, Inc. and the “Purchaser” Thereunder 8-K 001-35527 10.2 February 16, 2021 10.5 Purchase and Sale Agreement dated , 2021 between Emmaus Medical, Inc. and Prestige Capital Finance, LLC 8-K 001-35527 10.1 February 22, 2021 31.1+ Certification of Chief Executive Officer pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 * 31.2+ Certification of Chief Financial Officer pursuant of Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 * 32.1+ Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 * 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. 30 + This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. 31 EMMAUS LIFE SCIENCES, INC. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Emmaus Life Sciences, Inc. Dated: September 1, 2021 By: /s/ Yutaka Niihara Name: Yutaka Niihara, M.D., M.P.H. Its: Chief Executive Officer By: /s/ Yasushi Nagasaki Name: Yasushi Nagasaki Its: Interim Chief Financial Officer 32